foxo4 dri senolytic peptide human trial 2024 2025 The disordered p53 transactivation domain is the target of and the compound FOXO4-DRI Development of a novel senolytic
Description
Psychopharmacology (Berl) 1978;57:3338
In vitro studies show that downstream markers can vary sharply across cell type and tissue context, which is why reproducible sourcing and storage matter at the procurement stage
The criteria below reflect the standards clinics commonly use during an initial evaluation, though a full medical assessment always determines the final answer
doi: 10.1016/s0014-2999(02)01433-4
These claims are positioned as supporting general wellness rather than treating specific medical conditions
Arthroscopy, volume 0, September 9, 2024
